Background Approximately 50% of patients do not achieve seizure control with antiepileptic
drug (AED) monotherapy, and polytherapy, with more than one AED, is often required. To …

Epilepsy is one of the most common brain disorders, affecting more than 50 million people
worldwide. Although its treatment is currently symptomatic, the last generation of anti-seizure …

Background: As a third-generation antiseizure medication (ASM), lacosamide (LCM) is
recommended worldwide for patients with epilepsy. We aimed to provide more conclusive …

Policy scholars have effectively leveraged policy process models, theories, and frameworks
to respond to a variety of important environmental questions. For example, how do …

Objective We explored the efficacy and safety of lacosamide combined with inhibitors of fast-
inactivated sodium channels or with other antiepileptic drugs, in patients with drug refractory …

Lacosamide (LCM) is a new generation antiepileptic drug. It has only been available in Asia
in recent years. A retrospective study at two hospitals in Hong Kong was performed to …

This article provides the biologist, chemist, and clinician with an overview into currently
existing epilepsy medicines, an appreciation of those currently in development, and a …

INTRODUCTION: Lacosamide (LCM) is a new generation amino acid drug that is used in
patients with drug-resistant epilepsy, which increases the slow inactivation of voltage …

Tiagabina jako terapia dodana może być skuteczna w wybranych przypadkach padaczki
ogniskowej, a jej połączenie z lakozamidem wydaje się efektywne u pacjentów, u których …